Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Kidney Neoplasms 1Hemangiosarcoma 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 14Nivolumab 11Ipilimumab 10cabozantinib 6Axitinib 6belzutifan 5Radiosurgery 5atezolizumab 4Sunitinib 4palbociclib 3lenvatinib 3Surveys and Questionnaires 3Radiotherapy 3Pluvicto 3Everolimus 3Blood Specimen Collection 3Biopsy 3zimberelimab 2pazopanib 2cemiplimab 2Therapeutics 2Methods 2Magnetic Resonance Spectroscopy 2Irinotecan 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2trebananib 1toripalimab 1tocilizumab 1temsirolimus 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × trebananib × 1 year × Clear all
NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Dana-Farber Cancer Institute

Phase 1 Completed
62 enrolled 17 charts
DermatologicGastrointestinalGenitourinaryGynecologic

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡